Protocolo de uso de Albumina Humana al 20%

1 recurso en línea 3 p.Se entiende por MEDICAMENTO DE USO RESTRINGIDO a aquel para el que, mediante un procedimiento participativo, multidisciplinar y representativo del hospital, su uso ha sido restringido a determinados grupos de pacientes o a determinadas situaciones clínicas para asegurar una mayor eficacia, evitar efectos adversos, por motivos epidemiológicos o por motivos económicos. El Hospital Nacional de Clínicas (HNC) cuenta con un listado de medicamentos de uso restringido entre los que se encuentra la Albúmina Humana al 20% (AH).Fil: Bustos Fierro, Carolina. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Gavelli, María Emilia. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Herrera Comoglio, Raquel. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Calantoni, Miguel Alberto. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Breda, Susana Andrea. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.FIl: Bosio Beatriz. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Alesso, Luis. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Rueda, María José. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Kasparian, Andrés. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Zuázaga, Mariano. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Soria, Gustavo. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Ojeda, Verónica. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina.Fil: Arguello, Pablo. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Hospital Nacional de Clínicas; Argentina

Surface Modification of Sodium Montmorillonite Nanoclay by Plasma Polymerization and Its Effect on the Properties of Polystyrene Nanocomposites

Sodium montmorillonite nanoclay (Na+-MMT) was modified by plasma polymerization with methyl methacrylate (MMA) and styrene (St) as monomers and was denominated as Na+-MMT/MMA and Na+-MMT/St, respectively. This plasma modified nanoclay was used as reinforcement for polystyrene (PS) nanocomposites that were prepared by melt mixing. Pristine and modified Na+-MMT nanoclay were analyzed by the dispersion in various solvents, Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), and scanning electron microscopy (SEM). The results confirmed a change in hydrophilicity of the modified Na+-MMT, as well as the presence of a polymeric material over its surface. The pristine PS/Na+-MMT and modified PS/Na+-MMT/MMA and PS/Na+-MMT/St nanocomposites were studied with X-ray diffraction (XRD), differential scanning calorimetry (DSC), and TGA, as well as mechanical properties. It was found that the PS/Na+-MMT/St nanocomposites presented better thermal properties and an improvement in Young’s modulus (YM) in compared to PS/Na+-MMT/MMA nanocomposites

Cold plasma copolymer with antimicrobial activity deposited on three different substrates

Abstract A good strategy to prevent early deposition of bacteria that can form biofilms is the application of antimicrobial coatings to existing surfaces, however this field has been little explored and coatings are often non uniform in thickness. A homogeneous film of R-Carvone-Octadiene (ppCop) was deposited on different substrates (coverslip, minced coverslip and fabric) by cold plasma copolymerization to study the influence of the substrate on antimicrobial activity and show clues about the influence of octadiene on copolymerization. The ppCop showed better antimicrobial activity results on the substrate with higher effective contact area, highlighting the influence of this variable on antimicrobial activity. The ppCop deposited on minced coverslip showed an inhibition of E. coli and S. aureus bacteria by 48.69 ±0.08% and 49.31 ±0.58% respectively, with an average roughness of 14.1±0.02 nm and a static water contact angle of 79± 0.4°. The ppCop showed no cytotoxicity to the human cell line